Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

Lindor, Keith D., Kowdley, Kris V., Heathcote, Jenny E., Harrison, Edwyn M., Jorgensen, Roberta, Angulo, Paul, Lymp, James F., Burgart, Lawrence +1 more·2004·Hepatology
DOI 10.1002/hep.20092

Cited by (727)

Items 601–700 of 727

  1. Nonalcoholic Fatty Liver (NAFL): Overview
    Stephen Hugh Caldwell, Abdullah M. S. Al‐Osaimi, Charissa Chang, Christine A. Davis, Elizabeth Erickson Hespenheide, Lisa A Krugner-Higby, Anita Impaglizzo Hylton, Julia C. Iezzoni, Tri H. Le, Robert K. Nakamoto et al. · 2005
  2. Current and emergent therapies in the non-alcoholic fatty liver
    Alfredo Arredondo Bruce, Jacqueline Amores Carraté, Gustavo Guerrero Mejías · 2010 · Revista Archivo Médico de Camagüey
  3. ADVANCES IN TRANSLATIONAL SCIENCE
    Joseph H. Sellin, Sanjay K. Murthy, Martin Goetz, Arthur W. Hoffman, Ralf Kießlich · 2012
  4. Inflammatory and Anti-Inflammatory Mediators Secreted by Adipose Tissue
    Herbert Tilg, Alexander Rupert Moschen · 2009 · Oxidative stress and disease
  5. Steatosis hepatis
    Ulrich Baumann, Florian Puls · 2010 · Monatsschrift Kinderheilkunde
  6. Bile Acid as Therapeutic Agents
    Yoshihide Yamanashi, Tappei Takada, Hiroshi Suzuki · 2017 · Springer eBooks
  7. Non-alcoholic fatty liver disease associated with obesity: features ursodeoxycholic acid
    Д. И. Трухан, Билевич Ольга Анатольевна · 2019 · Meditsinskiy sovet = Medical Council
  8. Pleiotropic effects of ursodeoxycholic acid in patients with non-alcoholic steatohepatitis with impaired glycemic control
    A. A. Shipovskaya, Курбатова Ирина Валерьевна, Ольга Петровна Дуданова · 2020 · Экспериментальная и клиническая гастроэнтерология
  9. Nonalcoholic Fatty Liver Disease
    Anna Wieckowska, William D. Carey · 2010 · Elsevier eBooks
  10. Silymarin-choline combination versus ursodeoxycholic acid in non-alcoholic fatty liver disease: A randomized double-blind clinical trial
    Purba Chakrabarty, Mayukh Mukherjee, Rajasee Adhikary, Shatavisa Mukherjee, Souvik Majumder, Dipak Kumar Sarkar, Saubhik Ghosh · 2024 · Asian Journal of Medical Sciences
  11. Effect of Herbal Medicine on Insulin Signaling Pathways and Insulin Resistance in Metabolic Dysfunction-associated Fatty Liver Disease: A Review
    AMDS Karunaratna, Sagarika Ekanayake · 2024 · The Natural Products Journal
  12. Non alcoholic fatty liver disease (NAFLD): an overview
    NC McAvoy, Ann Lockman, P.C. Hayes · 2007 · The Journal of the Royal College of Physicians of Edinburgh
  13. Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open‐Label Dose‐Escalation Study
    Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Mamatha Reddy Dundigalla, Javeed Mohammad, Pavan Kumar Madala, Sanyasirao K. S. S. V. V. · 2025 · Advances in Pharmacological and Pharmaceutical Sciences
  14. Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins
    Mazen Noureddin, David Alexanian, Neil Kaplowitz · 2015 · Springer eBooks
  15. Antioxidant Approach to the Therapy of Chronic Liver Diseases
    Lê Thị Thanh Thủy, Hoang Hai, Norifumi Kawada · 2015 · Oxidative stress in applied basic research and clinical practice
  16. Abnormalities of Carbohydrate Metabolism and the Liver
    Shikha S. Sundaram, Estella M. Alonso · 2010 · Elsevier eBooks
  17. Pharmacologic Treatment Using Non-Hypoglycemic Agents for Nonalcoholic Fatty Liver Disease
    Seung Up Kim · 2018 · Journal of Korean Diabetes
  18. Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders
    Andrew J. Krentz, Pierre Bédossa · 2019 · Springer eBooks
  19. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article
    Sepideh Ahadi, Afshin Gharekhani, Afshin Shiva · 2019 · Arab Journal of Gastroenterology
  20. Dorfman-Chanarin Syndrome: A Rare Cause of Metabolic Associated Fatty Liver Disease Related to Homozygosity of the Nonsense Mutation c.934C>T (p.R312*)
    Rita Quelhas Costa, Francisco Laranjeira, Isaura Ribeiro, António Filipe Santos, Filipe Nery · 2021 · GE Portuguese Journal of Gastroenterology
  21. Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
    Wenkang Gao, Zhonglin Li, Huikuan Chu, Hang Yuan, Lilin Hu, Lin Yao, Li Rita Zhang, Weijun Wang, Rong Lin, Ling Yang · 2022 · Springer eBooks
  22. A Crohn's disease patient who developed nonalcoholic steatosis and cirrhosis of the liver after surgical excision of the small intestines
    Yoriko Higuchi, Kazufumi Dohmen, Shunichiro Ayabe, Hirofumi Tanaka, Masatora Haruno, Shinji Shimoda · 2008 · Kanzo
  23. Non‐alcoholic fatty liver disease guidelines: An Asian perspective
    Hiromasa Ishii, Mikio Kajihara · 2007 · Journal of Gastroenterology and Hepatology
  24. NASH Remains Without a Treatment … URSO They Say
    Jeffrey B. Schwimmer, Christian Braegger, Warren P. Bishop, Steven N. Lichtman, Joel R. Rosh, Jonathan E. Teitlebaum · 2004 · Journal of Pediatric Gastroenterology and Nutrition
  25. Pathogenesis and Management of Non-alcoholic Steatohepatitis
    Sang Hoon Park, Choong Kee Park · 2005 · Journal of the Korean Medical Association
  26. Clinical Use of Immunosuppressive Drugs to Control the Immune Response
    John M. Vierling · 2008 · Humana Press eBooks
  27. [Therapeuric aspects of NAFLD. A literature review].
    Norberto Carlos Chávez Tapia, Félix Ignacio Téllez-Ávila, Jorge García-Leiva, Martha Helena Ramos, J.F. Sánchez-Ávila, Misael Uribe · 2006 · PubMed
  28. Metabolic Syndrome and Non‐alcoholic Fatty Liver Disease
    Paul Angulo · 2016
  29. Nonalcoholic Fatty Liver Disease
    Poonam Mishra, Nila Rafiq, Zobair M. Younossi · 2008 · Cambridge University Press eBooks
  30. Therapeutic and Preventive Effects of a New Type Healthy and Viable Food Supplement on Fatty Liver and Blood Lipids in Animal Model
    Azam Bayat, Aref Khalkhali, Ali Reza Mahjoub · 2020
  31. Neue Therapiemöglichkeiten bei nichtalkoholischer Fettleber
    Thomas Pusl, Burkhard Göke · 2007 · Der Diabetologe
  32. Gibt es Therapieansätze für die nicht-alkoholische Fettleber und ihre Komplikationen?
    Stefan Strahl, Katharina Maier · 2008 · Der Internist
  33. Cost-effectiveness analysis of S-ademetionine compared with ursodeoxycholic acid for the treatment of Intrahepatic Cholestasis in China
    Han‐Soo Kim, Juntao Lyu, Ruth H. Royle, Kyoo il Kim, Mauricio Morales-Castillo, Joshua Byrnes · 2024 · Research Square
  34. Roles of ABCG5 ABCG8 cholesterol transporter in lipid homeostasis
    Yuhuan Wang · 2015 · UKnowledge (University of Kentucky)
  35. Efeito anti-fibrogênico do doador de óxido nítrico S-nitroso-N-acetilcisteína (SNAC) na esteato-hepatite não alcóolica experimental
    Daniel Ferraz de Campos Mazo · 2012 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  36. NASH - Diagnostik und Therapie: eine Übersicht
    Christian Zauner, Alois Zauner, Reem Abou Assi, Patrick Manfred Brunner, E Grafl, Eduardo Alexandre Hofstätter, Michael Kleinberger, Buko Lindner, C Putz, N Roszuzcky et al. · 2007 · Journal für Kardiologie (Krause & Pachernegg GmbH)
  37. Interventions thérapeutiques prometteuses dans un modèle in vivo de stéatohépatite non alcoolique
    Yara K. Haddad · 2008
  38. Pharmacological treatments for non-alcohol related fatty liver disease (NAFLD): a network meta-analysis
    Kurinchi Selvan Gurusamy, Douglas Thorburn, Brian Ritchie Davidson, Emmanuel A. Tsochatzis · 2015 · Cochrane Database of Systematic Reviews
  39. ESTUDIO DE LOS MECANISMOS PATOGÉNICOS DE LA HEPATITIS C Y SU RELACIÓN CON EL DESARROLLO DE ESTEATOSIS. EFECTO DE UN TRATAMIENTO ANTIOXIDANTE CON FLAVONOIDES
    Sandra Pisonero‐Vaquero · 2014 · Dialnet (Universidad de la Rioja)
  40. A New Stereo Method Based On The Detector Of Local Structures
    Bogusław Cyganek, Jan Borgosz · 2002 · INFM-OAR (INFN Catania)
  41. Hepatoprotectants Against Fatty Liver Disease: Antioxidants, Ursodeoxycholic Acid, and Herbal Medicines
    Anne-Catherine Bürgi, Jean‐François Dufour · 2013
  42. Intérêt des marqueurs sériques de mort cellulaire dans le spectre des stéatopathies métaboliques chez les obèses morbides
    Stéphanie Patouraux · 2013 · HAL
  43. Terapias actuales y emergentes en el hígado graso no alcohólico
    Alfredo Arredondo Bruce, Jacqueline Amores Carraté, Gustavo Guerrero Mejías · 2010 · Revista Archivo Médico de Camagüey
  44. Obesity and its Hepatic Complications in Adults and Children
    E. Jenny Heathcote, Eve A. Roberts · 2012
  45. Ist hochdosierte Ursodeoxycholsäure bei nichtalkoholischer Steatohepatitis effektiv?
    Jens Walldorf, Matthias Dollinger · 2010 · Die Gastroenterologie
  46. Molecular mechanisms of insulin resistance in chronic liver disease
    Christine Bernsmeier · 2008 · edoc (University of Basel)
  47. Liver Biopsy in Transplantation: Nonalcoholic Fatty Liver Disease and the Eosinophils
    Yasuhiko Sugawara, Norihiro Kokudo, Yoji Kishi · 2011 · InTech eBooks
  48. LIVER FAT IN THE METABOLIC SYNDROME AND TYPE 2 DIABETES
    Anna Kotronen · 2008 · Työväentutkimus Vuosikirja
  49. Glucagon-like peptide-1 in nonalcoholic steatohepatitis
    Matthew James Armstrong · 2014 · University of Birmingham Institutional Research Archive (University of Birmingham)
  50. 36 Gastrointestinal drugs
    Saleha Dar, Harry R. Dalton · 2007 · Side effects of drugs annual
  51. Use of ursodeoxycholic acid in patients with hypertransaminasemia
    Claudio Puoti, Maria Giuseppa Elmo · 2014 · Italian Journal of Medicine
  52. Leitfaden für die Praxis - Unklar erhöhte Transaminasen und die klinische Bedeutung der nichtalkoholischen Fettleber
    Max Karner, Wolfgang Stremmel · 2004 · Der Klinikarzt
  53. Nonalcoholic Fatty Liver Disease in Pediatric Patients
    Shikha S. Sundaram, Kristen J. Nadeau · 2009 · Obesity Management
  54. Chronic Hepatitis in Childhood
    Hassan H. A‐Kader, Fayez K. Ghishan · 2012 · Springer eBooks
  55. Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis
    Janet C. King, Kris V. Kowdley · 2007 · Hepatology
  56. Non-Alcoholic Fatty Liver Disease: Pathogenesis Directed Therapy – the Way Forward
    Norma C. McAvoy, Ann Lockman, Peter Clive Hayes · 2007 · Hungarian Medical Journal
  57. Regulatorische T-Zellen bei Erstdiagnose autoimmuner Lebererkrankungen - eine histologische und klinische Charakterisierung
    I. Medizinischen, Ansgar Wilhelm Lohse · 2012
  58. Non-alcoholic steatohepatitis: metabolic syndrome of the liver
    Christopher Paul Day · 2008 · Springer eBooks
  59. "Alterações hepáticas em grandes obesos: avaliações clínico-laboratoriais e histopatológicas antes do tratamento cirúrgico da obesidade"
    Cacilda Pedrosa de Oliveira · 2006
  60. Сучасні підходи до лікування неалкогольної жирової хвороби печінки на фоні метаболічного синдрому
    K. A. Prosolenko · 2012
  61. OPINION Nonalcoholic fatty liver disease: new treatments
    T.L. Hardy, Quentin Mark Anstee, Christopher Paul Day · 2015
  62. Stéatohépatite non alcoolique
    H. Castel, Philippe Mathurin · 2011 · EMC - Endocrinologie - Nutrition
  63. Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
    Samer Gawrieh, Naga Chalasani · 2015 · Springer eBooks
  64. Editorial NASH and thiazolidinediones: Not to be taken lightly q
    Jean-François Dufour · 2007
  65. 263 Chronic Hepatitis in Childhood
    2012 · SpringerReference
  66. Ursodiol for NASH Doesn't Work
    Kenneth D. Flora · 2004 · Journal watch
  67. 生活習慣と肝臓病：診断と治療の進歩 ＩＶ．非アルコール性脂肪肝炎（ＮＡＳＨ）６．ＮＡＳＨの治療
    河田 純男 · 2006 · Nihon Naika Gakkai Zasshi
  68. Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?
    Nae‐Yun Heo · 2016 · Korean Journal of Gastroenterology
  69. A Review of Pharmacological Treatments of NASH
    Érika Rabelo Forte de Siqueira · 2015 · Gastroenterology & Hepatology Open Access
  70. Fatty Liver Disease: A Wake Up Call
    HAM Nazmul Ahasan, Chandra Shekhar Bala, Sarmistha Biswas, Baharul Minnat, Homayra Tahseen Hossain · 2016 · Bangladesh Journal of Medicine
  71. What is the role of antifibrotic therapies in the current and future management of NAFLD?
    Natasha McDonald, Jonathan Andrew Fallowfield · 2016 · Wiley eBooks
  72. Hepatocellular-Cholangiocarcinomas in Non-Alcoholic Fatty Liver Disease: Evidence for Stem Cell Origin
    Paulo Giovanni L. Mendoza, Wilson M. S. Tsui, Lorraine Ho, Michael G. Wayne, Alexander Kagen, Neil David Theise · 2016 · Philippine Journal of Pathology
  73. Potential role of ursodeoxycholic acid and its side-chain modified derivatives in the treatment of non-alcoholic fatty liver disease and associated atherosclerosis
    Michael A Trauner, Peter Fickert, Tarek Moustafa, Andrea Fuchsbichler, Thierry Claudel, Emina Halilbasic, Dagmar Kratky, Helmut Denk · 2009 · Springer eBooks
  74. Are the guidelines—AASLD, IASL, EASL, and BSG—of help in the management of patients with NAFLD?
    Cristina Margini, Jean‐François Dufour · 2016
  75. Non-alcoholic steatohepatitis — therapeutic interventions
    Chris Day · 2009 · Springer eBooks
  76. Diagnóstico e Tratamento da Esteato ratamento da Esteato ratamento da Esteato ratamento da Esteato ratamento da Esteato-Hepatite Não Alcóolica -Hepatite Não Alcóolica -Hepatite Não Alcóolica -Hepatite Não Alcóolica -Hepatite Não Alcóolica Diagnosis and Treatment of Nonalcoholic Steatohepatitis
    Helena Cortez‐Pinto · 2006
  77. Hinweise auf Reduktion von Steatosis hepatis durch Metformin in vitro
    Stefanie Schramm · 2012 · Qucosa (Saxon State and University Library Dresden)
  78. MODELO EXPERIMENTAL DE ESTEATOHEPATITE NÃO-ALCOÓLICA COM DIETA DEFICIENTE EM
    Idilio Zamin, Ângelo Alves de Mattos, Eduardo Migon, Ernesto Soares, Marcos Barros Luiz, Santos Perry · 2009
  79. BENEFICIUL ACIDULUI URSODEOXICOLIC ÎN STEATOZA HEPATICĂ NON-ALCOOLICĂ LA COPIL
    Otilia Elena Frăsinariu, Laura Iulia Bozomitu, Alice Azoicăi, Bogdan Aurelian Stana, Paula Popovici, Evelina Moraru · 2013 · DOAJ (DOAJ: Directory of Open Access Journals)
  80. Diabetes and Non‐Alcoholic Fatty Liver Disease
    Shivakumar Chitturi, Geoffrey C. Farrell · 2016
  81. Factors Regulating Features of Metabolic Syndrome
    Sonja S. Pijut · 2017 · UKnowledge (University of Kentucky)
  82. An Update of Liver Transplantation for Nonalcoholic Steatohepatitis
    I. Raymond Thomason, Michael Charlton · 2015 · Current Hepatology Reports
  83. Tratamiento del hígado graso no alcohólico: ¿Qué sabemos?
    Juan Pablo, V Arab, C Carolina Ramírez, Ignacio Gran, P Arnoldo Riquelme, J Marco Arrese · 2010
  84. ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials
    Rohit Seth Loomba, ROBERT A. WESLEY, Frank Pucino, Tiebing Liang, David Erwin Kleiner, Joel E. Lavine · 2008
  85. Acute and Chronic Hepatitis
    Rima L. Fawaz, Maureen M. Jonas · 2010 · Elsevier eBooks
  86. Recent Advances
    Richard Kirsch, Pauline de la Μ. Hall, Jacob George, Arthur J. McCullough, Geoffrey C. Farrell · 2004
  87. Estudio de los mecanismos patogénicos de la hepatitis C y su relación con el desarrollo de esteatosis. Efecto de un tratamiento antioxidante con flavonoides = Study of the mechanisms involved in the development of steatosis associated to hepatitis C. Effects of antioxidant treatment with flavonoids
    Sandra Pisonero‐Vaquero · 2014
  88. Non-Alcoholic Fatty Liver Disease: What We Need to Know
    Luminiţa Leurzeanu, Laura Cârstocea · 2019 · Surgery Gastroenterology and Oncology
  89. Mecanismos patogénicos involucrados en el desarrollo de la esteatohepatitis no alcohólica en un modelo animal nutricional de ratón = Pathogenic mechanisms involved in the development of non alcoholic steatohepatitis in a nutritional mouse model
    Carmen Cecilia Almonacid Urrego · 2013
  90. Introductory Chapter: Nonalcoholic Fatty Liver Disease - What Should We Know?
    Emad Hamdy Gad, Yasmin Kamel · 2019 · IntechOpen eBooks
  91. Non Alcoholic Fatty Liver Disease- Is it a Rarity in Children of Bangladesh?
    ASM Bazlul Karim, Md Rukunuzzaman · 2020 · Bangladesh Journal of Child Health
  92. VII. The Evidence of Pharmacologic Treatment for NASH
    Masashi Yoneda · 2020 · Nihon Naika Gakkai Zasshi
  93. CLINICAL PROFILE OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS
    Sayed Mohammed Meraj Hussaini · 2015
  94. Deoxycholic and Ursodeoxycholic Acid Differentially Impact Cellular Steatosis and Lipid Peroxidation in Cultured Hepatoma Cells
    Laura Vergani, Francesca Baldini, Mohamad Khalil, Nadia Serale, Jacek Baj, Agostino Di Ciaula, Piero Portincasa · 2021 · The International Journal of Gastroenterology and Hepatology Diseases
  95. Identification of Shared Gene Signatures in Different Stages of Non-Alcoholic Fatty Liver Disease Using Integrated Microarray Dataset
    B. Fatemeh Nobakht M. Gh, Masoud Arabfard · 2020 · Research Square
  96. Abnormalities of Carbohydrate Metabolism and the Liver
    Cara Mack, Shikha S. Sundaram · 2021 · Elsevier eBooks
  97. Current World Literature
    2008 · Current Opinion in Lipidology
  98. Storage solutions
    Sofie M. A. Walenbergh · 2016
  99. Lifestyle Intervention and Vitamin E Therapy in Obese Children with Nonalcoholic Fatty Liver Disease
    Robabeh Ghergherehchi, Nazanin Hazhir, Manizheh Mostafa Gharehbaghi · 2012 · Journal of Comprehensive Pediatrics
  100. Ruolo dei farmaci non antidiabete nel trattamento della NAFLD
    Maurizio Russello, Maria Luisa Arpi · 2021 · il Diabete